This document provides an overview of the Positive Quality Intervention (PQI) for Revumenib (Revuforj), a drug used in the management of acute leukemia. It highlights the importance of multidisciplinary care, genomic testing, and patient-centered education in effectively administering Revumenib. The document details how Revumenib targets specific pathways in leukemia and discusses the necessity for close monitoring for side effects like QTc prolongation and differentiation syndrome. It emphasizes the role of medically integrated pharmacy models in ensuring safe and effective treatment, and outlines procedural guidelines for drug administration, monitoring, and patient education.
